Krystal Biotech, Inc. (NASDAQ:KRYS) Given Consensus Rating of “Buy” by Brokerages

Krystal Biotech, Inc. (NASDAQ:KRYS) has received a consensus recommendation of “Buy” from the eleven research firms that are presently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a hold rating, nine have issued a buy rating and one has issued a strong buy rating on the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $277.8889.

A number of equities analysts recently issued reports on KRYS shares. The Goldman Sachs Group increased their target price on shares of Krystal Biotech from $206.00 to $327.00 and gave the company a “buy” rating in a research report on Friday, January 30th. Zacks Research upgraded shares of Krystal Biotech from a “hold” rating to a “strong-buy” rating in a report on Wednesday, January 7th. Bank of America raised their price objective on shares of Krystal Biotech from $288.00 to $318.00 and gave the company a “buy” rating in a research note on Thursday, January 22nd. Guggenheim set a $224.00 target price on Krystal Biotech and gave the stock a “buy” rating in a research report on Friday, October 17th. Finally, Citigroup lifted their price target on Krystal Biotech from $320.00 to $336.00 and gave the company a “buy” rating in a research report on Monday, January 12th.

Krystal Biotech Price Performance

Shares of Krystal Biotech stock opened at $269.13 on Thursday. Krystal Biotech has a 1-year low of $122.80 and a 1-year high of $295.98. The business’s fifty day moving average price is $254.80 and its two-hundred day moving average price is $199.79. The company has a market capitalization of $7.80 billion, a P/E ratio of 40.35 and a beta of 0.49.

Krystal Biotech (NASDAQ:KRYS) last issued its quarterly earnings results on Monday, November 3rd. The company reported $2.66 EPS for the quarter, beating analysts’ consensus estimates of $1.12 by $1.54. Krystal Biotech had a return on equity of 19.36% and a net margin of 53.30%.The company had revenue of $97.80 million for the quarter, compared to analyst estimates of $93.72 million. On average, research analysts expect that Krystal Biotech will post 6.14 earnings per share for the current fiscal year.

Insider Transactions at Krystal Biotech

In related news, insider Suma Krishnan sold 25,000 shares of Krystal Biotech stock in a transaction dated Thursday, December 4th. The stock was sold at an average price of $220.16, for a total transaction of $5,504,000.00. Following the transaction, the insider directly owned 1,413,711 shares of the company’s stock, valued at $311,242,613.76. The trade was a 1.74% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 13.70% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Krystal Biotech

Several hedge funds have recently made changes to their positions in the business. Edgestream Partners L.P. acquired a new position in Krystal Biotech in the 2nd quarter worth approximately $2,705,000. Voya Investment Management LLC lifted its holdings in shares of Krystal Biotech by 46.7% in the third quarter. Voya Investment Management LLC now owns 93,908 shares of the company’s stock valued at $16,578,000 after purchasing an additional 29,915 shares in the last quarter. EFG Asset Management North America Corp. boosted its position in shares of Krystal Biotech by 18.4% in the third quarter. EFG Asset Management North America Corp. now owns 27,095 shares of the company’s stock worth $4,784,000 after buying an additional 4,217 shares during the period. State of New Jersey Common Pension Fund D boosted its position in shares of Krystal Biotech by 45.2% in the second quarter. State of New Jersey Common Pension Fund D now owns 15,033 shares of the company’s stock worth $2,066,000 after buying an additional 4,682 shares during the period. Finally, Norges Bank purchased a new position in shares of Krystal Biotech during the second quarter valued at $38,861,000. Institutional investors and hedge funds own 86.29% of the company’s stock.

About Krystal Biotech

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.